Columbia University has launched more than 147 companies based on technology developed at the University. Of these companies: 42 were venture-backed, 88 are active, and 27 have been sold or gone public.
Patrys is a publicly-listed company on the Australian Securities Exchange (ASX:PAB). The Company's headquarters are in Melbourne, Australia, and our main R&D center is in Würzburg, Germany, where our technology platform and product pipeline was first developed. Our principal focus is on the development of a completely new type of product for the treatment of cancer – natural human antibodies. These natural human antibodies offer the promise of increased potency coupled with greater safety as compared to existing cancer treatments.
After pioneering the microarray technology used to publish more than 20,000 scientific papers, Affymetrix is evolving into a provider of scalable, innovative genomic analysis tools and reagents for discovery, exploration, validation, and genetic testing. The acquisitions of Panomics and USB bring high-throughput, multi- to single-gene assays and premium-value molecular biology reagents to our customers, enabling a complete solution for genome-wide analysis studies and a range of products for cellular and protein analysis studies.
Alkeus Pharmaceuticals is a clinical stage biotechnology company focused on ophthalmic conditions with limited treatment options. Building on years of groundbreaking research in ophthalmology and on well-understood and validated biochemical processes, Alkeus has combined this knowledge to bring therapies from bench to bedside.
Allure Security Technology introduces a new way to secure your data. Data Leak Prevention (DLP) is a first step towards securing your data, but it does not prevent your sensitive information from being stolen and misused. Allure's new breakthrough technology enhancing DLP with traceable "decoy information" raises the level of protection to new unprecedented levels of safety and security.
Biotechnology company involved in the development and commercialization of novel therapeutic products for the treatment of cardiovascular diseases. Angioblast Systems specializes in the regrowth of adult stem cells for the repair and regeneration of blood vessels.
ARMGO Pharma, Inc., is a privately held biopharmaceutical company dedicated to applying original, targeted science to the discovery and development of novel small-molecule therapeutics to treat debilitating cardiac, muscular, and neurological disorders. The company’s proprietary drugs, known as “rycals,” are a new class of oral agents that act on a novel therapeutic target, the ryanodine receptor/calcium release channel (RyR) located on the sarcoplasmic/endoplasmic reticulum of the cell. Rycals act to stabilize these channels and repair the calcium leak caused by stress associated with chronic diseases. It is hypothesized that the leak in the RyR channels, if left untreated, may contribute to disorders affecting the heart, skeletal muscle, and the brain. Rycals have the potential to act selectively on these RyR channels, functioning as calcium release channel stabilizers. ARMGO Pharma, Inc., has been awarded an exclusive, worldwide license from Columbia University for its ryanodine receptor technology.
Bamboo Bike Studio is a resource for making bamboo bikes. We provide tools, kits, instructions and workshops that spread the art, science and joy of making bikes. Our goal is to create the opportunities for people to get the perfect bike… the one they build themselves. "We spread the love of bike-making by running build-your-own-bike workshops and selling build-your-own-bike kits. We’ve taught over two hundred and fifty people to make bikes at the Bamboo Bike Studio. Tens of thousands of miles of test riding. Riding through winter, through potholes and all over the world. We helped to start a factory in Ghana in September, with the goal of providing the lowest cost and highest value bicycles to people who want them most."
Biodesy has developed a unique and highly sensitive means of detecting conformational change in proteins and other biological molecules. Our technology, based on a phenomenon called 'second-harmonic generation' (SHG), can monitor structural change at any site within a protein, in real time.
Spun off in 2004 from Columbia University, Biosof LLC is a developer and provider of commercial software and services that help life scientists in the biopharmaceutical industry leverage genomics data to discover new drug leads, verify lab experiments and cut significant research time. Biosof’s products and services are embedded in business processes to achieve greater efficiencies while minimizing costs.
bluebird bio is developing innovative gene therapies for severe genetic disorders. At the heart of bluebird bio’s product creation efforts is its broadly applicable gene therapy platform for the development of novel treatments for diseases with few or no clinical options. The company’s novel approach uses stem cells harvested from the patient’s bone marrow into which a healthy version of the disease causing gene is inserted. After being grown in culture, those cells are given back to the patient. bluebird bio’s approach represents a true paradigm shift in the treatment of severe genetic diseases by eliminating the potential complications associated with donor cell transplantation and potentially presenting a one-time transformative therapy. bluebird bio has two later stage clinical products in development for childhood cerebral adrenoleukodystrophy (CCALD) and beta-thalassemia/sickle cell anemia. Led by a world-class team, bluebird bio is privately held and backed by top-tier life sciences investors, including Third Rock Ventures, TVM Capital, Forbion Capital Partners, Easton Capital and Genzyme Ventures. Its operations are located in Cambridge, Mass. and Paris, France.
CALM focuses on enabling companies to reduce energy costs and better manage risks, such as service reliability, through the use of our software-based energy services and CALM consulting services. We are passionately focused on enabling companies to reduce energy costs and better manage risks, such as service reliability, through the use of our software-based energy services and CALM consulting services. Our Smart Utility Management (SUM) Platform supports businesses in effectively dealing with data and to use advances in information technology as a competitive advantage, resulting in better management of risk and improved enterprise value through cost reductions and monetization of existing underutilized energy based resources.
Leader in Bring Your Own Device (BYOD) Mobile Multi-Persona solutions: Cellrox introduces the next generation of technology that enables employees and corporations to share a single fully functional mobile device without compromising security, performance, or user experience. By creating an impenetrable virtual wall between the employee's applications and the company's data and applications, Cellrox focuses on proactive security and application transparency all in a single swipe - one phone, two or more personas.
Chemcage SA's mission is to develop and enhance products and services intended for use in the field of Pharma R & D+I, based on nanotechnology, with excellent links to the international scientific sector.
Chromation designs and manufactures spectrometers for critical applications. The company’s patent-pending photonic crystal technology allows for the production of miniature spectrometers at a fraction of the cost of competitive technologies, enabling new markets as well as immediately addressing current markets.
CounterPath Corporation is a leading provider of innovative desktop and mobile VoIP software products and solutions. The Company's product suite includes SIP-based softphones, server applications and Fixed Mobile Convergence (FMC) solutions that enable service providers, enterprises and Original Equipment Manufacturers (OEM) to cost-effectively integrate voice, video, presence and Instant Messaging (IM) applications into their VoIP offerings and extend functionality across both fixed and mobile networks.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs.
eBrevia’s natural language processing software assists corporate attorneys, in-house counsel, and business executives in performing a variety of legal tasks more efficiently, accurately, and cost effectively. Using machine learning techniques, the company’s technology can extract and summarize legal provisions from a wide array of legal documents. Applications for the company’s products include due diligence, document management, and document drafting.
Emergent Communications offers the first NENA i3 Next Generation Internet Protocol (IP) standards based 9-1-1 emergency communications system. Emergent offers a hosted option for its PSAP Director and PSAPc Call Taker products for States, counties and large municipalities seeking a scalable and cost effective solution for IP enabling PSAPs. The Emergent hosted PSAP Director and Call taker solutions offer full Next Gen call taking capabilities at the PSAP for a fraction of the cost of premise based hardware solutions. Our "Software as a Service" (SaaS) model is unique to the Emergency Communications Services Industry and represents the application of IP based technologies, ubiquitous throughout enterprises and organizations, into the emergency communications market. The Emergent hosted model takes full advantage of the compelling economics of cloud computing.
Fifth Generation Computer Corporation has been an innovator of design solutions since the Company’s inception. We have developed products for a variety of industrial and military uses. Our goal is to expand our design solution services in partnership with our business partners and others.
Genia's mission is to make genetic information universally available. Our proprietary integrated circuits and NanoTag chemistry enable massively parallel single-molecule DNA sequencing. This versatile nanopore-based platform allows for single molecule, electrical, real-time analysis without the need for complicated optics, labels, amplification, or fluidics. By developing a true integrated circuit on standard semiconductor process technology, Genia's sequencing platform enables the use of molecular diagnostics in everyday clinical care.
Health Fidelity, Inc. is a leading healthcare big data company. REVEAL, our breakthrough clinical NLP platform, built around the world's most accurate, reliable and studied NLP technology, enables real-time extraction, normalization, structuring and coding of unstructured information for a multitude of healthcare applications such as quality measurement and analytics, electronic health records, clinical decision support, medical transcription, and revenue cycle management. These applications rely on the power of REVEAL to enable end users to make more accurate, timely and evidence-based clinical decisions, monitor and improve care quality, drive operational efficiency and accelerate healthcare transformation.
Intelligent Bio-Systems was founded in 2005 by Drs. Steven J. Gordon and Jingyue Ju to commercialize an advanced DNA sequencing system. Dr. Gordon previously founded Intelligent Automation Systems, which was responsible for a number of key instrumentation solutions which helped to complete the Human Genome Project. Dr. Ju is one of the key inventors of fluorescent energy transfer dyes used in most electrophoresis-based sequencers.
IntelliVi was created to commercialize visualization technology for minimally invasive surgery licensed from Columbia University. It is the belief of the company founders that the technology will enable the evolution of advanced surgical procedures and robotics surgery while reducing cost in currently performed minimally invasive procedures.
Kilimanjaro Energy is developing technologies to capture carbon dioxide from the air for beneficial commercial use in a variety of existing and new industries. Our technologies will economically capture CO2 wherever and whenever it is needed. Atmospheric CO2 is a vast resource whose transformation into useful products can help humanity close the carbon cycle. Kilimanjaro’s core technology was discovered by Dr. Klaus Lackner and Allen Wright with the generous financial support of the late Gary Comer and the Comer Science & Education Foundation. As of 2010, the Company has begun commercializing its developments with the added support of ARCH Venture Partners.
The LuminAID solar light proposes a new direction for solar technology. Flexible, photovoltaic film is laminated to polyethelenevinyl acetate plastic (PEVA). The LuminAID solar light inflates to produce a quality of light similar to a lantern. The LuminAID solar light provides 5 hours of light and fully charges in 6 hours. The inflatable core measures 9" L x 9" W. Printed on the core is a frit pattern that consists of white dots. The frit pattern diffuses the LED light like a lantern and is intended for use in disaster relief.
Lumiode is developing a brand new microdisplay platform that is 30 times brighter and 5-10 times more efficient than other technologies. This is possible by taking advantage of the LED and directly pixelating the light emitting materials. We are currently investigating both visible light applications (microdisplays, head-mounted displays, projection displays, head-up displays) and non-visible light applications (depth scanning, 3D printing). Lumiode's devices will fulfill the need for a high brightness, low power consumption, and compact form factor system required for current and emerging application areas.
MELA Sciences is a medical technology company focused on developing MelaFind, a non-invasive and objective multi-spectral computer vision system intended to aid in the detection of early melanoma. MELA Sciences designed MelaFind to assist in the evaluation of clinically atypical pigmented skin lesions, when a dermatologist chooses to obtain additional information before making a final decision to biopsy to rule out melanoma.
Memory Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery and development of drug candidates for the treatment of central nervous system conditions. It offers drugs for neurological diseases associated with aging, such as Alzheimer’s disease, as well as psychiatric disorders, such as schizophrenia, cognitive impairment associated with schizophrenia (CIAS), and depression. The company’s products include MEM 1003, a neuronal L-type calcium channel modulator that is in phase II clinical trials for the treatment of Alzheimer’s disease and bipolar disorder; and nicotinic alpha-7 agonists, including MEM 3454, a phase IIa clinical trial product and MEM 63908, a phase I clinical trial product for the treatment of Alzheimer’s disease and CIAS. Its products also comprise PDE4 inhibitors, including MEM 1414, a phase I clinical trial program, as well as MEM 1917 for CNS disorders and depression; PDE10 Inhibitor program; and 5-HT6 Antagonists for the treatment of Alzheimer’s disease, schizophrenia, attention deficit disorder, and obesity. The company has collaborations with F. Hoffman-La Roche, Ltd. for the development of nicotinic alpha-7 agonists; and Amgen, Inc. for the development of PDE10 inhibitors. In addition, it has a development agreement with The Stanley Medical Research Institute to develop MEM 1003 as a treatment for bipolar disorder. The company was incorporated in 1997 and is based in Montvale, New Jersey. As of December 31, 2008, Memory Pharmaceuticals Corp. operates as a subsidiary of Hoffmann-La Roche Inc.
We are the world’s leading packager of patent pools for standards and other technology platforms used in consumer electronics, as well as chemical, eCommerce, education, energy, environment, healthcare and biotechnology, manufacturing and materials, transportation and wireless technology. We developed the pool market space. (view link) Our business model supports a large number of patent users – creating reasonable access and profitable opportunities for all parties.
Musically Intelligent Machines automatically describe music. Our software listens to music and automatically tags ("autotags") it with the descriptions that fit it best from a vocabulary of about a hundred tags. Once we've tagged the music, you can search by autotag and browse through music that has been described similarly.
Nanosys was founded in 2001 to drive a materials revolution, bringing the best IP in the field of inorganic nanomaterials and chemistry to bear on the innovation challenges faced by visionary manufacturers. Our mission is to architect materials from naturally occurring elements with properties that are well-understood at the nanoscale, to help companies create amazing new products – like electronic devices with better color LCD displays and batteries with longer performance.
We are Nephros, Inc., a modern medical device company proud to be pioneers and innovators of first-in-class therapies and products that create a better quality of life for the populations we serve. We are dedicated to providing End Stage Renal Disease patients and other immuno-compromised patients with new, innovative and efficacious therapies to improve their quality of life.
PCAsso Diagnostics is a research and development committed to the development and marketing of novel diagnostic technologies.
Pharmacopeia, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to address significant medical needs. Its internal program portfolio comprises PS433540, a dual-acting angiotensin and endothelin receptor antagonist, which is in phase II clinical development for the treatment of cardiovascular and renal diseases, including hypertension and diabetic nephropathy; and PS178990, a muscle selective SARM agonists that is in phase I clinical development. The company’s products also include PS031291, a preclinical development product for the treatment of multiple myeloma and various inflammatory diseases, including rheumatoid arthritis; and JAK3 inhibitors for T-cell and cytokine mediated dermatologic and ocular diseases, such as psoriasis and dry eye. Pharmacopeia has strategic alliances with Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals. The company was founded in 1993. It was formerly known as Pharmacopeia Drug Discovery, Inc. and changed its name to Pharmacopeia, Inc. in May 2007. Pharmacopeia is based in Cranbury, New Jersey. As of December 23, 2008, Pharmacopeia, Inc. operates as a subsidiary of Ligand Pharmaceuticals Inc.
Progenics Pharmaceuticals, Inc., of Tarrytown, NY, is a biopharmaceutical company with programs in gastroenterology, oncology and virology focused on innovative therapeutics for patients with debilitating conditions and life-threatening diseases.
Radiator Labs was founded in March 2011 based on the idea that steam-fed radiator heat is inherently wasteful. Approximately 15% of the heat produced in the New York City metropolitan area is wasted due to the overheating of apartments, equivalent to $480 million dollars each year. The Radiator Labs system eliminates this waste with a low-cost, drop-in solution by integrating a radiator enclosure, which controls how much heat gets transferred into a room, with wireless capabilities, allowing communication to the boiler room of a building. In combination this system allows buildings to equalize temperature across all apartments while burning fuel only when necessary, saving the majority of waste heat while vastly improving apartment comfort.adiatorlabs.com
Raytheon Trusted Computer Solutions is part of Raytheon’s Intelligence and Information Systems business. RTCS develops and deploys cross domain solutions that enable government and civilian agencies to share and access information securely across multiple classified networks at different classification levels. RTCS’ certified and accredited cross domain solutions help customers protect sensitive and classified information while ensuring that the sensitive information gets to the correct people in a timely manner.
Reata Pharmaceuticals was founded in 2002 and is on a mission to translate innovative science into breakthrough medicines for serious and difficult to treat diseases. Reata is the leader in developing a novel class of oral anti-inflammatory drugs, Antioxidant Inflammation Modulators (AIMs), which are potent activators of the biological transcription factor Nrf2. Nrf2 controls the body's production of hundreds of antioxidants and has shown strong potential to protect against a broad range of diseases associated with inflammation and oxidative stress.
RemoteReality is the designer and manufacturer of ultra wide-angle computational cameras and video systems. Using our unique patented optics, the latest in image sensors, and our own advanced video processing, our solutions deliver high resolution real time, low latency video for a variety of cutting edge applications. Our video solutions are available in both day and night configurations, spanning the visible, LWIR and MWIR spectra.
Acquired by Evotec AG, Renovis, Inc. is a biopharmaceutical company which discovers, develops, and commercializes drugs for the treatment of neurological and inflammatory diseases in the United States. It engages in preclinical research and development, including molecular biology, medicinal chemistry, in vitro and in vivo pharmacology, drug metabolism, pharmacokinetics, toxicology, and informatics. The company’s proprietary preclinical programs are focused on identifying antagonists of selected purinergic receptors as novel potential treatments for a range of pain and inflammatory conditions. It focuses on identifying and developing treatments for pains, such as osteoarthritic pain or pain associated with osteoarthritis, and neuropathic pain or nerve pain. The company was founded in 2000 and is based in South San Francisco, California. As of May 2, 2008, Renovis Inc. operates as a subsidiary of Evotec AG.
RST is committed to pushing the technological envelope to introduce a new era of robotic devices to automate repetitive, error-prone, costly, and time-consuming instrument processing functions throughout the hospital. RST's latest product , PenelopeCS, will revolutionize the way hospitals manage their inventory of surgical instruments. PenelopeCS will help automate some key functions in the hospital's sterile supply department, where used/dirty surgical instruments are cleaned, sorted, inspected, and repacked into containers, to be sterilized for the next procedure.
Our software solutions and services are used by researchers, manufacturers, systems integrators, and service providers to address design challenges ranging from the physics of component design to the business implications of planning wired and wireless networks.
Schrödinger is a scientific leader in computational drug design for pharmaceutical and biotechnology research. Schrödinger makes significant investments in R&D, which has led to major advances in the field of computational chemistry. Working closely with its scientific advisory board – a distinguished group of leading academic and industrial scientists who collectively have over one thousand publications with over 50,000 citations – Schrödinger has achieved breakthroughs in quantum chemistry, molecular modeling, force fields, molecular dynamics, protein structure determination, and docking. Schrödinger's methods development and applications papers have over one thousand citations and are often among the most-cited scientific publications. Schrödinger's science is extensively validated by its growing legion of loyal users.
Scoople provides a family of news applications delivering intelligent aggregation on the iPhone. This includes the right content: only the most relevant news selected from high-quality sources; and the right format: every story is summarized from the sources covering it.
Silver Lining is a stealth startup backed by top-tier VCs and software industry luminaries.
Headquartered in Sunnyvale, California, Starion Instruments™, a Microline Surgical Company, develops innovative solutions for open and laparoscopic surgery using simple yet highly effective technologies. Starion’s devices perform an essential part of surgery, sealing and dividing soft tissue. However, Starion's instruments achieve this through the application of direct heat and pressure. All of Starion’s products are based on the company’s proprietary Tissue Welding technology, licensed exclusively from Columbia University. By using only direct heat and pressure to simultaneously seal and divide tissue, Starion's instruments can minimize unintended thermal injury and be used adjacent to vital and delicate tissue structures with less risk than other technologies. As a result, Starion's products are used in a wide variety of open and endoscopic cardiac, gynecological, general surgical, otolaryngologic and urologic surgical procedures.
Synceros, Inc. specializes in the commercialization of patented and superior approaches to single-camera 3D imaging. Our technology is applicable to the entertainment, security, industrial markets and the medical device market. The medical device market, while potentially lucrative, will serve as a later stage target market after a successful multi-phase launch into more easily bridged industrial markets.
Acquired by EMC Corp, System Management ARTS, Inc. provides event automation and root-cause analysis for faults across networks, servers, and applications. The company provides enterprise software to manage various IT assets, including computer networks, systems, and applications. Its InCharge platform automatically pinpoints root cause problems in real time and calculates their impacts. System Management solutions automatically map the infrastructure, monitor, and correlate the data across complex relationships to diagnose the authentic problem. The company was founded in 1993 and is headquartered in White Plains, New York.
NY-based company that helps you customize your own wardrobe. You pick the fabric, and the color, then give the measurements and the garment is made especially for you.
Time Medical Systems (TM) was founded in 2006 by Professor Ma and his leadership team, comprised of an international group of scientists, engineers, clinicians, healthcare executives and business leaders in finance, public policy and solutions marketing. With more than 100 published papers and 15 patents, the group owns a strong intellectual property portfolio including the IP transferred from Columbia University and University of Hong Kong. TIME MEDICAL Systems is the first company to develop and deploy HTS Coil Technology for use with clinical MRI scanners. HTS Coil Technology has been proven effective at overcoming the Signal-to-Noise Ratio (SNR) limitations of conventional copper RF coils.
Vital View is a highly innovative company developing new imaging technologies aimed for the medical market. Its first product, the VitalView1000, is designed for cervical and uterine visualization for improved methods of embryo deposit during embryo transfer in IVF procedure.
Under license from Columbia University, Vizio has developed a novel and proprietary family of medical devices based on Dr. Ed Leonard’s microfluidic technology for separating plasma from blood: ultrafiltration (removal of excess fluid) as an adjunct to hemodialysis and for congestive heart failure, and kidney dialysis. The company’s first product is a small, lightweight unit that removes excess fluid on the days between dialysis sessions, based on the nephrologist’s uploaded prescription. It will be worn continuously at the waist and connected by a catheter. It will be simple to operate and will not require anticoagulants, medical supervision or a trained caregiver. A similar device for congestive heart failure patients will be worn episodically several days a month, as an alternative to hospitalization or drug therapy, with treatment regulated by hemodynamic data from their implanted heart monitor or defibrillator. From the patient’s perspective, Vizio offers a simple device that improves quality of life by regularly alleviating the burden of excess fluid and reducing the number of weekly dialysis treatments. From the dialysis center’s perspective, the device will be the only cost-effective solution for complying with the new Medicare “conditions of coverage” regulations, an unfunded mandate for each patient’s treatment plan to be optimized to remove excess fluid and attain normal blood pressure without medications.